Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
Dateline City:
KENILWORTH, N.J.
One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time
New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that Sam...
Source: Merck.com - Research and Development News - November 5, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Amgen Boosts Outlook as Profit Rises 50%
Amgen raised its 2015 guidance as the biotechnology company reported that its third-quarter earnings rose 50% on stronger revenue led by Enbrel and other key drugs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - October 28, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news
Sandoz's BLA for biosimilar etanercept gets FDA acceptance
The US Food and Drug Administration (FDA) has accepted Novartis company Sandoz's biologics licence application (BLA) under the 351(k) pathway for etanercept, a biosimilar to Amgen's Enbrel drug. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 4, 2015 Category: Pharmaceuticals Source Type: news
Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - October 2, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Enbrel Alone an Option After Remission in RA (CME/CE)
(MedPage Today) -- Etanercept responders may not need to stay on methotrexate, study suggests (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 18, 2015 Category: Geriatrics Source Type: news
Etanercept Mitigates New Lesions in Axial Spondyloarthritis (CME/CE)
(MedPage Today) -- Multiple measures of disease activity improved with 3 years of treatment (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 16, 2015 Category: Geriatrics Source Type: news
Merck, Samsung Bioepis Win Biosimilar Approval
Merck and Samsung Bioepis announced the approval of a biosimilar version of Amgen's immunology medicine Enbrel by the Ministry of Food and Drug Safety in Korea. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 8, 2015 Category: Pharmaceuticals Source Type: news
Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea
Dateline City:
KENILWORTH, N.J. & SEOUL, South Korea
First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide
KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS™
(etanercept), a biosimilar of the immunology medicine Enbrel, by the
Ministry o...
Source: Merck.com - Product News - September 8, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck and Samsung Bioepis Announce Approval of BRENZYS ™ (Etanercept), a Biosimilar of Enbrel, in Korea
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. & SEOUL, South Korea < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Sy...
Source: Merck.com - Product News - September 8, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Case Study: PBC Responds to Anti-TNF Agent (CME/CE)
(MedPage Today) -- Symptoms abated after Enbrel started, and returned when it was stopped (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 26, 2015 Category: Gastroenterology Source Type: news
As psoriasis maintenance therapy, step-down matched full-dose etanercept for quality of life measures
At 6 months, quality of life is largely the same whether psoriasis patients stay on their initial etanercept (Enbrel) dose of 50 mg twice weekly or step down to 50 mg once weekly with topical corticosteroids, according to a Canadian trial published in the Journal of The European Academy of... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 22, 2015 Category: Dermatology Source Type: news
Enbrel Kept Axial Spondyloarthritis at Bay for 48 Weeks (CME/CE)
(MedPage Today) -- Improvement seen in symptoms and objecttive inflammation measures (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 22, 2015 Category: Geriatrics Source Type: news
Amgen to pay $71 million to settle claims of off-label drug uses
Biotechnology company Amgen Inc. has agreed to pay $71 million to 48 states and the District of Columbia to settle claims that it improperly promoted its top-selling drugs, Aranesp and Enbrel, for uses not approved by the Food and Drug Administration.
California will receive $4.6 million from the settlement, Attorney General Kamala Harris announced Tuesday.
Harris and the other attorneys general alleged that Amgen (Nasdaq: AMGN) violated state consumer protection laws by promoting Aranesp for dosing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Source Type: news
Texas to share in $71M California pharma company settlement
The State of Texas will build up its bank account as a result of Thousand Oaks, California-based Amgen Inc.’s decision to settle a multi-state investigation stemming from allegations it unlawfully promoted biologic medications Aranesp and Enbrel for off-label uses.
Amgen has agreed to pay $71 million to 49 states, including Texas, to resolve the matter, according to Texas Attorney General Ken Paxton. Texas’ share of the settlement is $4.3 million.
Aranesp is a treatment for anemia, and Enbrel… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 19, 2015 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news
Amgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing CaseAmgen Pays $71 Mln to Settle Enbrel, Aranesp Marketing Case
Amgen Inc has reached a $71 million settlement with 48 states and the District of Columbia to resolve claims that the company promoted its drugs Enbrel and Aranesp for uses not approved by the FDA. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 19, 2015 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
